p53-miR-34a feedback in lung fibroblasts regulates antifibrotic effects of CSP7, nintedanib, and pirfenidone
American Journal of Physiology-Lung Cellular and Molecular Physiology · 2025
DOI: 10.1152/ajplung.00295.2024 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Physiology-Lung Cellular and Molecular Physiology, 2025. Verfasst von Liang Fan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular and Molecular Biology, Texas Lung Injury Institute, The University of Texas Health Science Center at Tyler, Tyler, Texas, Unit…. Hauptthemen laut MEDLINE: MicroRNAs, Pyridones, Tumor Suppressor Protein p53, Fibroblasts. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCI NIH HHS, NIEHS NIH HHS.
Abstract (Originalsprache)
Pulmonary fibrosis is a progressive and fatal fibroproliferative disease. The current drugs (nintedanib/pirfenidone) only slow clinical progression. Myofibroblasts are the primary effector cells of PF. We found that CSP7, nintedanib and pirfenidone exert antifibrotic effects through restoring p53-microRNA-34a feedback induction in lung (myo)fibroblasts. We further found that daily treatment of mice with CSP7/nintedanib/pirfenidone between days 14 and 21 post-bleomycin lung fibrosis improve survival, body weight and lung function, and combination therapy had added benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cellular and Molecular Biology, Texas Lung Injury Institute, The University of Texas Health Science Center at Tyler, Tyler, Texas, United States.
- Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, Texas, United States.
- Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States.
- Pulmonary Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States.
ORCID-Profile: Huy Minh Dao, Akarsha Balnadupete, Deborah E Citrin, Robert O Williams, Jay I Peters, Sreerama Shetty
Förderung
- NHLBI NIH HHS
- NCI NIH HHS
- NIEHS NIH HHS
- HHS | NIH | National Heart, Lung, and Blood Institute
- HHS | NIH | National Institute of Environmental Health Sciences
Zitieren
APA
Fan, L., Shetty, R. S., Dao, H. M., Balnadupete, A., Somasundram, B., Bhagavath, A. K., Kongara, A., Tang, H., Citrin, D. E., Williams, R. O., Peters, J. I., & Shetty, S. (2025). p53-miR-34a feedback in lung fibroblasts regulates antifibrotic effects of CSP7, nintedanib, and pirfenidone. American Journal of Physiology-Lung Cellular and Molecular Physiology. https://doi.org/10.1152/ajplung.00295.2024
Vancouver
Fan L, Shetty RS, Dao HM, Balnadupete A, Somasundram B, Bhagavath AK, et al. p53-miR-34a feedback in lung fibroblasts regulates antifibrotic effects of CSP7, nintedanib, and pirfenidone. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2025. doi:10.1152/ajplung.00295.2024
BibTeX
@article{Fan2025,
author = {Fan, Liang and Shetty, Rashmi S and Dao, Huy Minh and Balnadupete, Akarsha and Somasundram, Bharath and Bhagavath, Ashoka Kumar and Kongara, Akhila and Tang, Hua and Citrin, Deborah E and Williams, Robert O and Peters, Jay I and Shetty, Sreerama},
title = {p53-miR-34a feedback in lung fibroblasts regulates antifibrotic effects of CSP7, nintedanib, and pirfenidone},
journal = {American Journal of Physiology-Lung Cellular and Molecular Physiology},
year = {2025},
doi = {10.1152/ajplung.00295.2024}
}
EUVIMED